Selection of a lead candidate for the development of an ASO therapeutic for NF1 cognitive and social deficits - neurofibromatosis type 1 (NF1) is an autosomal dominant disorder affecting 1 in 3,000…
Active Grant Awarded
- Award ID
- R43NS147645
- Recipient
-
Infixion Bioscience Inc. UEI F6B4DQXKDSE8
- Awarding agency
-
National Institute of Neurological Disorders and Stroke
National Institutes of Health, Department of Health and Human Services
- Obligated
- $478,799
Award facts
- Assistance listing
- 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders
- Completion date 12% complete
- Place of performance
- San Diego, CA 92121, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, National Institute of Neurological Disorders and Stroke awarded Infixion Bioscience Inc. $478,799 on August 26, 2026, under grant R43NS147645, Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853). The award funds selection of a lead candidate for an antisense oligonucleotide (ASO) therapeutic to treat cognitive and social deficits in neurofibromatosis type 1 (NF1). The recipient proposes steric-blocking ASOs that target microRNA regulation of NF1 expression to increase NF1 protein levels, normalize RAS and other altered signaling, and mitigate NF1-related cognitive and social deficits at their source. The approach is designed to be mutation-agnostic across the NF1 mutation spectrum. The period of performance ends August 31, 2028, and work is performed in San Diego, California (ZIP 92121). The assistance type is a grant. The program funds extramural research on the structure and function of the brain and nervous system and on reducing the burden of neurological disease. The source identifies no sub-recipients for this award.
Description
Selection of a lead candidate for the development of an ASO therapeutic for NF1 cognitive and social deficits - neurofibromatosis type 1 (NF1) is an autosomal dominant disorder affecting 1 in 3,000 births and over 2.5 million people worldwide. Up to 80% of individuals with NF1 experience cognitive and social deficits (CSDS), including impairments in attention, executive function, learning, memory, and social development, often diagnosed as autism. These challenges significanuy impact academic performance, necessitate individualized education plans (IEPS), and contribute to increased anxiety, depression, loneliness, reduced employment opportunities, and lower quality of life. Despite their prevalence, NF1-associated CSDS remain an unmet clinical need, with no approved therapies direcuy addressing their root cause. Current therapeutic efforts primarily focus on downstream NF1 signaling targets, such as MEK inhibition, which fail to comprehensively address NF1-associated pathophysiology. Since NF1 is a haploinsufficient disorder, restoring NF1 protein levels represents a promising therapeutic approach. Given that micrornas (MIRNAS) regulate NF1 expression, we propose a novel strategy using steric-blocking antisense oligonucleotides (SBASOS) to increase NF1 protein levels, normalize RAS and other altered signaling, and mitigate NF1-related CSDS at their source. This mutation-agnostic approach holds potential for broad clinical impact across the diverse spectrum of NF1 mutations. Research background increasing NF1 protein expression has been shown to reverse RAS hyperactivation, and overcomrg haploinsufficiency has demonstrated therapeutic benefit in other haploinsufficient genetic disorders ( e.g., SIM1, PAX6). By leveraging SBASOS as highly specific gene-targeting agents, we aim to develop a mutation-agnostic CNS therapy for NF1, addressing CSDS in the vast majority of NF1 individuals, regardless of their specific NF1 mutation. Specific aims we will develop and validate lead sbaso drug candidates for N F1 CSDS by 1) designing and screening SBASOS targeting the NF1 3'UTR to block mirna binding and enhance NF1 protein levels, 2) verifying specificity and functional impact on NF1 protein expression in a CNS-relevant cell line, and 3) demonstrating in vivo efficacy I1 an NF1-relevant mouse model. By the end of this program, we will establish in vivo proof-of-conceptfor NF1 haploinsufficiency correction using SBASOS. This will position infixion for intellectual property (IP) protection, a phase 2 sbir grant, and pharmaceutical partnerships for follow-on efficacy, safety, and toxicity studiesadvancing a first-in-class therapeutic approach for NF1-associated CSDS.
Quick answers
Who received award R43NS147645?
R43NS147645 was awarded to Infixion Bioscience Inc. by National Institute of Neurological Disorders and Stroke (National Institutes of Health) on August 26, 2026.
How much is award R43NS147645 worth?
$478,799 has been obligated on R43NS147645.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award